• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.

作者信息

Kalra Ankur, Hawkins Edward S, Nowacki Amy S, Jain Vardhmaan, Milinovich Alex, Saef Joshua, Thomas George, Gebreselassie Surafel K, Karnik Sadashiva S, Jehi Lara, Young James B, Svensson Lars G, Chung Mina K, Mehta Neil

机构信息

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute (A.K., J.S., M.K.C.), Cleveland Clinic, OH.

Section of Cardiovascular Research, Heart, Vascular and Thoracic Department, Cleveland Clinic Akron General, OH (A.K.).

出版信息

Circ Cardiovasc Qual Outcomes. 2020 Oct;13(10):e007115. doi: 10.1161/CIRCOUTCOMES.120.007115. Epub 2020 Aug 28.

DOI:10.1161/CIRCOUTCOMES.120.007115
PMID:32856462
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7578112/
Abstract
摘要

相似文献

1
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers: A Comparison of Outcomes in Patients With COVID-19.血管紧张素转换酶抑制剂与血管紧张素II受体阻滞剂：COVID-19患者结局比较
Circ Cardiovasc Qual Outcomes. 2020 Oct;13(10):e007115. doi: 10.1161/CIRCOUTCOMES.120.007115. Epub 2020 Aug 28.
2
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.中国 2 家中心回顾性研究：血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂在高血压合并 COVID-19 患者中的持续使用效果。
Med Sci Monit. 2020 Sep 24;26:e926651. doi: 10.12659/MSM.926651.
3
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用与新型冠状病毒病 2019（COVID-19）检测阳性的关联。
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026. doi: 10.1001/jamacardio.2020.1855.
4
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
5
Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.新型冠状病毒肺炎患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用、胃肠道症状与死亡率之间的关联
Gastroenterology. 2020 Sep;159(3):1170-1172.e1. doi: 10.1053/j.gastro.2020.05.034. Epub 2020 May 16.
6
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
7
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
8
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
9
Related molecular mechanisms of COVID-19, hypertension, and diabetes.新型冠状病毒肺炎、高血压和糖尿病的相关分子机制
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E881. doi: 10.1152/ajpendo.00164.2020.
10
A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).关于血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂在2019冠状病毒病（COVID-19）中应用的共识声明。
N Z Med J. 2020 Apr 3;133(1512):85-87.

引用本文的文献

1
Interaction of COVID-19 With Common Cardiovascular Disorders.COVID-19 与常见心血管疾病的相互作用。
Circ Res. 2023 May 12;132(10):1259-1271. doi: 10.1161/CIRCRESAHA.122.321952. Epub 2023 May 11.
2
[Differences among renin-angiotensin system inhibitor drugs in prognosis of hypertense patients with COVID-19].[肾素-血管紧张素系统抑制剂药物在COVID-19高血压患者预后中的差异]
Arch Cardiol Mex. 2022 Apr 7;93(Supl 6):58-65. doi: 10.24875/ACM.21000185.
3
The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.

本文引用的文献

1
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用与新型冠状病毒病 2019（COVID-19）检测阳性的关联。
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026. doi: 10.1001/jamacardio.2020.1855.
2
COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?新冠病毒感染相关的高黏滞血症：炎症与血栓形成倾向之间的联系？
Lancet. 2020 Jun 6;395(10239):1758-1759. doi: 10.1016/S0140-6736(20)31209-5. Epub 2020 May 25.
3
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
免疫系统、肾素-血管紧张素-醛固酮系统（RAAS）与 RAAS 抑制剂之间的相互作用可能会调节 COVID-19 的转归：系统评价。
J Clin Pharmacol. 2021 Aug;61(8):987-1000. doi: 10.1002/jcph.1852. Epub 2021 Apr 7.
4
COVID-19: immunopathology, pathophysiological mechanisms, and treatment options.COVID-19：免疫病理学、病理生理学机制和治疗选择。
J Pathol. 2021 Jul;254(4):307-331. doi: 10.1002/path.5642. Epub 2021 Mar 25.
5
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报7：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对2019冠状病毒病感染的风险及影响
Ann Intern Med. 2021 Feb;174(2):W25-W29. doi: 10.7326/L20-1446. Epub 2021 Jan 5.
6
High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy.COVID-19 相关急性肾损伤需要肾脏替代治疗的幸存者中，肾脏恢复率较高。
PLoS One. 2020 Dec 28;15(12):e0244131. doi: 10.1371/journal.pone.0244131. eCollection 2020.
7
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.血管紧张素转换酶 2（ACE2）药理学调控的综合指南，该酶是 SARS-CoV-2 的进入受体。
Pharmacol Ther. 2021 May;221:107750. doi: 10.1016/j.pharmthera.2020.107750. Epub 2020 Dec 1.
8
Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.高血压、药物治疗与重症 COVID-19 风险：一项基于马萨诸塞州社区的观察性研究。
J Clin Hypertens (Greenwich). 2021 Jan;23(1):21-27. doi: 10.1111/jch.14101. Epub 2020 Nov 21.
肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Angiotensin II, tissue factor and the thrombotic paradox of hypertension.血管紧张素II、组织因子与高血压的血栓形成悖论
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1723-9. doi: 10.1586/erc.10.161.
6
Regulation of ACE2 in cardiac myocytes and fibroblasts.心肌细胞和成纤维细胞中血管紧张素转换酶2（ACE2）的调节
Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2373-9. doi: 10.1152/ajpheart.00426.2008. Epub 2008 Oct 10.
7
Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats.健康大鼠在血管紧张素转换酶（ACE）抑制和饮食钠限制期间肾血管紧张素转换酶（ACE）和血管紧张素转换酶2（ACE2）的差异调节
Exp Physiol. 2008 May;93(5):631-8. doi: 10.1113/expphysiol.2007.041855. Epub 2008 Jan 11.
8
Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.缓激肽在介导血管紧张素转换酶抑制剂对人体血管作用中的作用。
Circulation. 1997 Mar 4;95(5):1115-8. doi: 10.1161/01.cir.95.5.1115.